Cervical Cancer is the fourth most common type of cancer and the fourth leading cause of death in women.
As per DelveInsight, cervical cancer incidence by 2020 is estimated to be 43,712 in the 7MM.
Cervical Cancer Market is anticipated to increase with a modest CAGR of 16.9% for the study period of 2017-2030 in 7MM. Recent progress in the technology, emerging immunotherapies targeted therapies, and vaccines as monotherapy or in concomitance with chemos are expected to improve cervical cancer treatment landscape.
Several pharma companies are proactively exploring novel treatment options to treat cervical cancer. Some of the key companies in the cervical cancer market includes Regeneron, AstraZeneca, Iovance, Zeria Pharmaceutical, Seattle Genetics, Genmab, Agenus Bio, Roche, Akeso Biopharma, and Vaccibody.
For more details visit:
https://www.delveinsight.com/blog/cervical-cancer-market/